Author | Philip W. Kantoff, MD | OncLive

Author | Philip W. Kantoff, MD

Articles

Dr. Kantoff on Docetaxel Plus Androgen Deprivation Therapy in Prostate Cancer

January 26, 2017

Video

Philip W. Kantoff, MD, chair of the Department of Medicine, Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care winner for Genitourinary Cancer, discusses the combination of docetaxel (Taxotere) chemotherapy and androgen deprivation therapy (ADT) in the setting of metastatic hormone-sensitive prostate cancer.

Dr. Kantoff on Evolving Role of Docetaxel in Prostate Cancer Treatment

November 18, 2016

Video

Philip W. Kantoff, MD, chairman of Medicine at Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care winner for Genitourinary Cancer, discusses the role that chemotherapy treatment with docetaxel will continue to have in patients with prostate cancer. Kantoff shared this insight in an interview during the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

x